lung cancer	is a	malignancy
lung cancer	originates in	bronchial epithelium
lung cancer	is classified as	small cell
lung cancer	is classified as	non‑small cell
small cell lung cancer	is aggressive
non‑small cell lung cancer	is slower
lung cancer	is diagnosed with	CT scan
lung cancer	is diagnosed with	PET scan
lung cancer	is diagnosed with	biopsy
lung cancer	is staged by	TNM system
lung cancer	is staged as	stage I
lung cancer	is staged as	stage IV
lung cancer	is treated with	surgery
lung cancer	is treated with	chemotherapy
lung cancer	is treated with	radiation
lung cancer	is treated with	targeted therapy
lung cancer	is treated with	immunotherapy
surgery	removes	tumor
chemotherapy	uses	cisplatin
chemotherapy	uses	paclitaxel
radiation	delivers	ionizing radiation
targeted therapy	inhibits	EGFR
targeted therapy	inhibits	ALK
immunotherapy	blocks	PD‑1
immunotherapy	blocks	CTLA‑4
EGFR mutation	predicts	gefitinib response
ALK rearrangement	predicts	crizotinib response
PD‑L1 expression	predicts	pembrolizumab response
smoking	causes	lung cancer
passive smoke	increases risk of	lung cancer
radon exposure	increases risk of	lung cancer
asbestos exposure	increases risk of	mesothelioma
asbestos exposure	increases risk of	lung cancer
lung cancer	causes	cough
lung cancer	causes	hemoptysis
lung cancer	causes	weight loss
lung cancer	causes	dyspnea
lung cancer	causes	chest pain
lung cancer	causes	anemia
lung cancer	leads to	metastasis
metastasis	occurs in	brain
metastasis	occurs in	bone
metastasis	occurs in	liver
metastasis	occurs in	adrenal
brain metastasis	causes	seizures
bone metastasis	causes	fractures
liver metastasis	causes	jaundice
adrenal metastasis	causes	hormonal imbalance
lung cancer	increases risk of	venous thromboembolism
lung cancer	increases risk of	pneumonia
lung cancer	increases risk of	respiratory failure
lung cancer	increases risk of	death
lung cancer	is associated with	poor prognosis
early stage	improves	survival
late stage	reduces	survival
biomarker	predicts	treatment response
KRAS mutation	predicts	poor response to EGFR therapy
p53 mutation	predicts	aggressive disease
tumor mutational burden	predicts	immunotherapy benefit
LDH level	predicts	tumor burden
CEA level	predicts	recurrence
prognostic score	predicts	overall survival
performance status	predicts	treatment tolerance
age	predicts	treatment choice
gender	predicts	incidence
race	predicts	incidence
comorbidity	predicts	mortality
cardiovascular disease	predicts	treatment complications
COPD	predicts	postoperative risk
renal function	predicts	chemotherapy toxicity
liver function	predicts	chemotherapy toxicity
body mass index	predicts	survival
nutrition status	predicts	recovery
social support	predicts	adherence
health literacy	predicts	self‑management
insurance status	predicts	access to care
geographic location	predicts	treatment availability
hospital volume	predicts	surgical outcomes
oncologist experience	predicts	survival
clinical trial enrollment	improves	outcomes
palliative care	improves	quality of life
palliative care	reduces	hospital readmission
palliative care	reduces	opioid use
symptom management	reduces	distress
early detection	reduces	mortality
screening	reduces	late presentation
low-dose CT	reduces	lung cancer mortality
smoking cessation	reduces	recurrence
exercise	improves	functional status
diet	improves	immune function
supplementation	reduces	side effects
pharmacogenomics	guides	dosing
real‑world evidence	informs	guidelines
electronic health record	supports	risk stratification
machine learning	predicts	relapse
biobank	provides	research material
patient‑reported outcomes	guide	therapy adjustments
telemedicine	increases	follow‑up adherence
multidisciplinary team	improves	coordination
clinical pathway	standardizes	care
